Archive
All News
Every briefing, headline, and filing we've published, newest first.
PolicySTAT News ↗
Health insurers would have likely faced a financial strain by participating in the Medicare pilot.…
PipelineEndpoints News ↗
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
PolicyKFF Health News ↗
Section 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is req…
DataDrug Channels ↗
By Adam J. Fein, Ph.D.Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty …
DealsFierceBiotech ↗
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
PolicyFiercePharma ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
PolicyBriefing
HHS Secretary Robert F. Kennedy Jr. defended a proposed $16B budget cut, including $5B from NIH, as Republican…
DealsPharmaceutical Technology ↗
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.…
PipelineSTAT News ↗
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
PolicyEndpoints News ↗
Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedit…
DealsEndpoints News ↗
LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in ce…
Deals
Lilly’s $3.25 billion upfront acquisition of Kelonia Therapeutics signals a bold move into in‑vivo CAR‑T techn…
PeoplePharmaVoice ↗
Where the rumored frontrunner stands on key issues like vaccines and public health policy.…
PolicyFierceBiotech ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
PipelineBriefing
Enflonsia, now cleared across the EU and EEA, promises single-dose, five-month protection against RSV, positio…
PipelineBioPharma Dive ↗
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
MoneyEndpoints News ↗
A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, t…
PipelineSTAT News ↗
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening …
PeopleFiercePharma ↗
Just two months after the FDA accepted for review Teva’s long-acting version of a decades-old schizophrenia dr…
PeopleFiercePharma ↗
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as …
PeopleFiercePharma ↗
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
For Astellas’ chief manufacturing officer, Rao Mantri, Ph.D., production is not just about a reliable supply o…
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyFierceBiotech ↗
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
PeopleSTAT News ↗
As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.